We also observed significant reductions of αIIbβ3 (as detected by two different mAb clones against CD41, the αIIb subunit) and GPVI, but not FcγRIIA (CD32), in CLL platelets independently of ibrutinib treatment when compared to healthy control platelets (Figure 3B). This evidence concerns the gene FCGR2A and B-cell chronic lymphocytic leukemia.